Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
M., Goldberg, G
Blackford, A
Patients enrolled in the PIONEER 2 [15], PIONEER 3 [16], SUSTAIN 2 [17], and SUSTAIN 8 [18] trials had type 2 diabetes that was uncontrolled by metformin (with or without sulfonylurea) and were treated with an additional oral/subcutaneous GLP-1RA (semaglutide), oral SGLT-2i (empagliflozin/canagliflozin), or oral DDP-4i (sitagliptin)
At the same time, competition is intensifying, with new drugs demonstrating improved efficacy, such as therapies achieving up to 15.3% weight loss and 1.7%2.0% HbA1c reduction in trials
Six-month results also reflect the cumulative benefit of sustained appetite control and modified eating patterns becoming habitual
US$ 22.22
US$ 20.08
US$ 22.52
US$ 23.46
US$ 22.39
US$ 21.05
US$ 25.78
US$ 25.47
